DNAtrix Awarded Most Promising Life Science Company at 2015 Texas Life Science Forum
Houston, TX – DNAtrix was named one of the Most Promising Life Science Companies at the 2015 Texas Life Science Forum held in Houston, Texas on May 20, 2015.
The Texas Life Science Forum is the largest Life Science commercialization and venture conference in the Southwest. The conference featured industry luminary speakers, investors, and companies from throughout the U.S., while showcasing Texas research and innovations. Life Science companies presented their technologies to an audience of 600 investors, entrepreneurs, biopharmaceutical companies, researchers, service providers and other members of the life science community.
The one-day event culminated in an announcement of the Most Promising Life Science Companies chosen from 55 competitors and judged by venture capital investors attending the forum. DNAtrix presented the clinical progress of its lead program, DNX-2401, in glioblastoma. The data from the completed Phase I recurrent malignant glioma trial conducted at MD Anderson Cancer Center was reviewed as well as progress in ongoing clinical trials in the US and EU.
DNAtrix is a clinical stage, venture-backed biotechnology company headquartered in Houston, Texas. Its lead product, DNX-2401, is an oncolytic virus that is being developed as an immunotherapy for glioblastoma. The Company has been awarded a 3-year grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at http://www.dnatrix.com.
Imran Alibhai, Ph.D.